Daratumumab and blood-compatibility testing

New England Journal of Medicine

Volumn 375, Issue 25, 2016, Pages 2497-

  Bueno, José Luis ^a   Alarcón, M D Ana ^a   Krsnik, M D Isabel ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DARATUMUMAB;

BLOOD ANALYSIS; BLOOD COMPATIBILITY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HUMAN; LETTER; MYELOMA; PHYSICIAN; PRIORITY JOURNAL; MULTIPLE MYELOMA;

HUMANS; MULTIPLE MYELOMA;

EID: 85007087410     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1613868     Document Type: Letter

References (4)

1. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319-31.
2. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754-66.
3. Murphy MF, Dumont LJ, Greinacher A. Interference of new drugs with compatibility testing for blood transfusion. N Engl J Med 2016;375:295-6.
4. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015;55:1545-54.